OncoMatch

OncoMatch/Clinical Trials/NCT04166006

A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.

Is NCT04166006 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Autologous DC vaccine and Interleukin-2 for head neck tumors.

Phase 2RecruitingIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSNCT04166006Data as of Jun 2026Location: Italy

Treatment: Autologous DC vaccine · Interleukin-2Single-arm, monocentric trial to assess safety and immunological efficacy of adjuvant vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV rare cancers (In Head/Neck tumors (H\&N), NEuroendocrine Tumors (NET) and Soft Tissue Sarcomas (STS).

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Autologous DC vaccineInterleukin-2

Cancer type

Neuroendocrine Tumor

Sarcoma

Disease stage

Required: Stage IV

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: surgery — radical intent

surgically treated with radical intent

Lab requirements

Blood counts

Haemoglobin >10 g/dl; WBC ≥3000/μl; ANC ≥1500/μl; platelets ≥75000/μl

Kidney function

serum creatinine <1.5x upper institutional reference level

Liver function

AST and ALT <3x upper institutional reference level; total bilirubin <1.5x upper institutional reference level

Cardiac function

Patients aged 70 years or older must have left ventricular ejection fraction not lower than 55% as assessed by echocardiography

Haemoglobin >10 g/dl; White blood cells ≥3000/μl; Absolute neutrophil count ≥1500/μl; Platelets≥75000/μl; AST and ALT <3x upper institutional reference level; Total bilirubin <1.5x upper institutional reference level; Serum creatinine <1.5x upper institutional reference level. Patients aged 70 years or older must have left ventricular ejection fraction not lower than 55% as assessed by echocardiography.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT04166006 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received surgery.

What disease stage is eligible?

Stage IV is required.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify